BioCentury
ARTICLE | Company News

SciClone cancer news

November 2, 2009 8:00 AM UTC

SciClone will restructure and reduce headcount by seven (17%) to 34, with cuts primarily in research and development. In October, SciClone discontinued a Phase II of RP101 to treat advanced pancreatic...